Twist Bioscience Stock Price, News & Analysis

Twist Bioscience reported record revenues for fiscal 2021 at $132.3 million, marking a 47% increase from $90.1 million in fiscal 2020. Growth is attributed to strong performance in SynBio, NGS, and Biopharma sectors. The company expects revenues of $183 million to $193 million for fiscal 2022. Despite the revenue growth, the net loss widened to $152.1 million, or $3.15 per share. The company had $477.9 million in cash as of September 30, 2021, supporting future investments in biopharma and data storage.

Twist Bioscience Corporation (NASDAQ: TWST) announced the acquisition of Abveris, a private company specializing in in vivo antibody discovery, for up to $190 million. The deal consists of $150 million in common stock and cash at closing, with up to $40 million contingent on Abveris meeting revenue targets. This acquisition aims to enhance Twist's capabilities in antibody design and discovery, integrating various methods including synthetic libraries and AI. A conference call is scheduled for 8:00am ET to discuss further details.

Twist Bioscience Corporation (NASDAQ: TWST) has announced an extension of its partnership with Invetx, focused on developing monoclonal antibodies for animal health. This new phase incorporates next-generation synthetic antibody phage display technology to discover innovative therapeutic candidates for diseases affecting dogs and cats. The collaboration aims to enhance antibody optimization through complementary in vitro capabilities, complementing Invetx’s in vivo platforms. Twist’s extensive synthetic antibody libraries are already in use to identify potential drug candidates for various veterinary applications.

Twist Bioscience Corporation (NASDAQ: TWST) announced the launch of Revelar Biotherapeutics, Inc., an independent biotechnology company focused on developing an antibody that neutralizes all known SARS-CoV-2 variants. Revelar will utilize Twist Biopharma's antibody discovery platform, with potential for licensing up to five additional therapeutics in four years. Twist is set to receive over $100 million in milestone payments and royalties from Revelar. Investment of up to $10 million from Twist is also planned, alongside significant minority ownership in Revelar.

Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust will present at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, at 3:20 p.m. Eastern Time. The presentation will be available for live streaming on the company's investor relations website, with a replay accessible for 30 days post-event. Twist is a leader in synthetic biology, utilizing a proprietary silicon-based DNA synthesis platform to create a wide array of synthetic DNA products for various sectors, including healthcare and agriculture.

Twist Bioscience Corporation (NASDAQ: TWST) will announce its fiscal 2021 fourth quarter and full-year financial results on November 22, 2021, before the market opens. A conference call for analysts and investors will follow at 8:00 a.m. Eastern Time, providing insights into the financial outcomes and business updates. Financial results will be accessible on the company’s website prior to the call. Twist is recognized for its innovative DNA synthesis platform, manufacturing various synthetic DNA-based products for multiple industries including healthcare and agriculture.

Twist Bioscience has launched Exome 2.0, boasting the most comprehensive coverage of protein-coding and noncoding regions of the genome. This innovative product enhances sequencing efficiency with lower costs and best-in-class performance, offering improved uniformity and a higher on-target rate. The Exome 2.0 is designed for applications addressing rare diseases and inherited disorders. The release underscores the company's commitment to supporting genomics researchers with customizable and efficient solutions.

Twist Bioscience has announced a collaboration with the Broad Institute to distribute the Twist Alliance Clinical Research Exome, a next-generation sequencing panel targeting genes related to cancer and inherited diseases. Designed using validated clinical data, this panel enhances sequencing efficiency and supports the Broad's efforts in processing over 250,000 samples. It will be available mid-October, combining various genomic regions to facilitate deeper insights into genetic variants for therapeutic applications.